In 114 virologically suppressed adults with HIV-1, switching to once-daily doravirine plus raltegravir led to one virological failure by week 48 (1.3%) vs none with continued therapy, and none more through week 96. Three treatment-related adverse events led to stopping.
RCTn = 114
Palich et al. Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL)